rAAV-based and intraprostatically delivered miR-34a therapeutics for efficient inhibition of prostate cancer...

Area of Science:

• Oncology
• Molecular Biology
• Gene Therapy

Background:

• Prostate cancer (PCa) currently lacks effective treatments.
• MicroRNA-34a (miR-34a) is consistently downregulated in PCa, suggesting its potential as a therapeutic target.
• Modulating miR-34a expression may offer a novel strategy for PCa treatment.

Purpose of the Study:

• To investigate the therapeutic potential of restoring miR-34a expression in a preclinical model of prostate cancer.
• To evaluate the efficacy of adeno-associated virus serotype 9 (AAV9)-mediated delivery of miR-34a for inhibiting PCa progression.

Main Methods:

• Verified miR-34a downregulation in prostate tumors from the transgenic adenocarcinoma mouse prostate (TRAMP) model.
• Overexpressed miR-34a in PCa cells in vitro to assess its impact on cell cycle, viability, and migration.
• Administered intraprostatic injections of rAAV9 carrying pri-miR-34a into TRAMP mice to evaluate in vivo therapeutic effects.

Main Results:

• Overexpression of miR-34a inhibited PCa cell cycle, viability, and migration by targeting downstream genes.
• Intraprostatic delivery of rAAV9·pri-miR-34a in TRAMP mice significantly reduced tumor burden and neoplasia.
• The treatment led to a significant decrease in body weight and a notable extension of lifespan in treated mice.
• Confirmed downregulation of target genes by overexpressed miR-34a in vivo.

Conclusions:

• Demonstrated that miR-34a restoration can effectively inhibit prostate cancer progression.
• Established the feasibility and efficacy of AAV9-mediated intraprostatic delivery of miR-34a as a therapeutic strategy for PCa.
• Highlights the potential of targeting miR-34a for future prostate cancer therapies.